Use of intraoperative beuromonitoring in Thyroid cancer surgery patients

Phase III, Assessor blinded, randomised controlled trial of the use of intraoperative neuromonitoring (IONM) in thyroid cancer surgery - IONM

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/05/019419

Enrollment

448

Registered

2019-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C73- Malignant neoplasm of thyroid gland

Interventions

Intervention1: IONM: Arm 1 (IONM) Intubation and Tube position Intubation will be done by the anesthesiologists in a normal fashion with monitoring EMG-Endotracheal tube (EMG-ET) which are available

Eligibility

Inclusion criteria

Inclusion criteria: Total thyroidectomy with or without central compartment dissection. Redo total/completion thyroidectomy

Exclusion criteria

Exclusion criteria: Patients operated for benign diseases Hemithyroidectomy Pre operative cord ï¬?xity High risk for intraoperative RLN sacriï¬?ce as determined by the treating surgeon Redo patients undergoing unilateral procedures Patients unwilling to participate in the trial

Design outcomes

Primary

Measure	Time frame
temporary RLN palsy between D1- D 21 after surgeryTimepoint: at 6 months,and at end of 2 years	—

Secondary

Measure	Time frame
Patients with RLN palsy: FOL evaluation, voice assessments Patients without RLN palsy: only voice assessments Timepoint: 6 monthly follow up upto 2 years	—

Countries

India

Contacts

Public ContactDr Gouri Pantvaidya

Tata Memorial hospital

docgouri@gmail.com9833971155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026